What is Faeth Therapeutics?
Faeth Therapeutics is a clinical-stage biotechnology firm focused on pioneering metabolism-based cancer treatments. Leveraging advanced AI-driven computational biology, precision nutrition, and targeted therapeutics, the company aims to identify and exploit metabolic vulnerabilities within tumors. This innovative approach seeks to significantly improve cancer treatment outcomes and accelerate the development of novel oncology programs. The company's strategy positions it at the forefront of precision oncology, addressing a critical need for more effective and personalized cancer therapies.
How much funding has Faeth Therapeutics raised?
Faeth Therapeutics has raised a total of $92M across 3 funding rounds:
Angel/Seed
$20M
Series A
$47M
Other Financing Round
$25M
Angel/Seed (2022): $20M with participation from Khosla Ventures, S2G Ventures, and Future Ventures
Series A (2022): $47M led by Future Ventures, S2G Ventures, and Khosla Ventures
Other Financing Round (2025): $25M supported by Future Technologies, Khosla Ventures, S2G Ventures, and Digitalis Ventures
Key Investors in Faeth Therapeutics
Khosla Ventures
Khosla Ventures is a venture capital firm that provides strategic advice and funding to technology entrepreneurs, with a broad investment focus including AI and health.
S2G Ventures
S2G Ventures is a venture fund focused on the food and agriculture sectors, investing in companies that address evolving consumer demands for healthy and sustainable products.
Future Ventures
Future Ventures backs mission-driven founders with unique ideas, focusing on seed and early-stage investments in disruptive technologies and industries.
What's next for Faeth Therapeutics?
The substantial capital infusion, characterized as a major enterprise-level funding and a strategic investment, indicates Faeth Therapeutics is poised for significant scaling and advancement of its clinical pipeline. This backing will likely fuel further research and development, potentially expanding its therapeutic targets and accelerating the progression of its lead candidates through clinical trials. The company's focus on AI and computational biology suggests a continued emphasis on data-driven innovation, aiming to solidify its position as a leader in the oncology therapeutics sector. Future growth may involve strategic partnerships or expanded clinical study initiatives to validate its unique approach to cancer treatment.
See full Faeth Therapeutics company page
